Nasopharyngeal carcinoma
Conditions
Interventions
group 1:IMRT alone
group 2:IMRT pius cisplatin concurrent chemoradiotherapy
Sponsors
651 East Dongfeng Road, East, Guangzhou, China
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Histologic diagnosis of nasopharyngeal carcinoma (WHO II or III); 2. stage II and III (AJCC 7th edition); 3. pre-treament EB DNA level=70; 8. Hepatic function: STB, CB=4.0*10^9/L, ANC>=1.5*10^9/L; PLT >=100*10^9/L; HB>=90g/L; 10. Voluntary to participate sign informed consent document; 11. Compliance with regular follow-up; 12. Compliance with the test requirements.
Exclusion criteria
Exclusion criteria: 1. Previously treated (surgery, chemotherapy, radiotherapy, EGFR targeted therapy or immunotherapy); 2. Distant metastases; 3. Pregnancy; 4. Refuse to sign informed consent document; 5. Uncontrolled seizure disorder or other serious neurologic disease; 6. in other clinical trial; 7. Allergic to Chemotherapy drugs; 8. With severe complications or active infection; 9. Organs dysfunction(heart,lungs and etc); 10. TBIL>1.5(ULN)AST or ALT>2.5 ULN and ALP>2.5 ULN; 11. Mental disorders, chronic diarrhea, ascites or pleural effusion; 12. Immunosuppressive therapy for other diseases; 13. History of other cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete remission rate;Overall survival;Quality of life; | — |
Countries
China
Contacts
Public ContactGuo Xiang
Department of Nasopharyngeal, Sun Yat-sen University Cancer Centre
Outcome results
None listed